Table 1.
Clinical and biologic characteristics of CBF patients treated on COG AAML0531 stratified by KIT mutational status
| Characteristic | No KIT Mutation (N = 142) | KIT Mutation (N = 63) | P-value |
|---|---|---|---|
| Male,N (%) | 72 (51%) | 31 (49%) | 0.843 |
| Age,median (range in years) | 11.55 (0.33–22.53) | 11.96 (0.61–22.76) | 0.689 |
| CBF | 0.288 | ||
| t (8;21) | 72 (51%) | 27 (59%) | |
| Inv(16)/t(16;16) | 70 (49%) | 26 (41%) | |
| Race | |||
| American Indian or Alaskan Native | 1 (1%) | 0 (0%) | 1.000 |
| Asian | 2 (2%) | 4 (8%) | 0.666 |
| Native Hawaiian or Other Pacific Islander | 0 (0%) | 0 (0%) | 1.000 |
| Black or African American | 16 (13%) | 8 (15%) | 0.691 |
| White | 103 (84%) | 40 (77%) | 0.236 |
| Unknown | 20 | 11 | |
| Ethnicity | 0.596 | ||
| Hispanic | 33 (24%) | 17 (27%) | |
| Not Hispanic | 105 (76%) | 45 (73%) | |
| Unknown | 4 | 1 | |
| WBC×103uL – median (range) | 34.15 (1–432) | 39.6 (2–335.5) | 0.487 |
| Platelet count – median (range) | 42 (5–477) | 22 (2–252) | 0.002 |
| BM blast % - median (range) | 56 (6–100) | 73.5 (22–100) | <0.001 |
| Chloroma present | 38 (0–98) | 57 (0–95) | 0.001 |
| Central nervous system Positive | 22(15%) | 4 (6%) | 0.075 |
| CEBPA Positive | 0 (0%) | 1 (2%) | 0.249 |
| NPM1 positive | 0 (0%) | 0 (0%) | 1.000 |
| FLT3/ITD Positive | 4 (4%) | 2 (3%) | 1.000 |
| Treatment Allocation | 0.358 | ||
| Arm A (No GO) | 73 (51%) | 28 (44%) | |
| Arm B (GO) | 69 (49%) | 35 (56%) | |
| CR End Induction 1 | 117 (82%) | 52 (83%) | 0.98 |